Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Shi Hu

Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.

scientific article published on 8 March 2017

Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.

scientific article published on 17 September 2013

Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.

scientific article published on 26 August 2016

Cardiac adenovirus-associated viral Presenilin 1 gene delivery protects the left ventricular function of the heart via regulating RyR2 function in post-ischaemic heart failure

scientific article

Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody

scientific article

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

scientific article

Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.

scientific article

Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.

scientific article

Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic

scientific article published on 16 June 2020

RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody

retracted scientific article

Structural Basis for Treating Tumor Necrosis Factor   (TNF )-associated Diseases with the Therapeutic Antibody Infliximab

scientific article

Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site

scientific article

Structure basis for the unique specificity of medaka enteropeptidase light chain

scientific article

The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.

scientific article published on 09 December 2013

Treatment of murine lupus with PD-LIg

scientific article published on 23 October 2015

Paulina is supported by:

About Paulina

Help